TRINETRA › Sectors › Healthcare
Indraprastha Medical Corporation Limited (INDRAMEDCO) — share price, P/E and fundamentals
Indraprastha Medical Corporation Limited (NSE: INDRAMEDCO) closed at ₹305.65 on 30 Oct 2026, -45.1% over one year, against a 52-week range of ₹294.80 – ₹640.85.
In the quarter ended 30 Sept 2026 (standalone, filed 29 Oct 2026) it reported revenue of ₹413 cr and net profit of ₹54 cr, a 13.0% net margin; revenue grew 8.4% and profit grew 8.7% year on year.
On four consecutive filed quarters its trailing P/E is 14.6; since 16 May 2025 its own P/E has ranged from 14.4 to 35.5 (median 21.4), and today's reading is higher than 0% of those 360 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 26.3%, ROCE 33.0%, debt-to-equity 0.00, Piotroski F-score 5 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 52% of 64 sector peers; PBT margin higher than 48% of 64 sector peers; ROE higher than 89% of 64 sector peers.
Key figures
| Last close | ₹305.65 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -17.5% / -24.8% / -45.1% |
| 52-week low – high | ₹294.80 – ₹640.85 |
| Market capitalisation | ₹2,802 cr |
| Trailing P/E | 14.6 |
| Price / book | 3.44 |
| EV / EBITDA | 9.0 |
| Earnings yield | 6.9% |
| TTM EPS | ₹20.96 |
| TTM net profit | ₹192 cr |
| Quarter revenue | ₹413 cr |
| Quarter net profit | ₹54 cr |
| Net margin | 13.0% |
| Revenue growth (YoY) | +8.4% |
| Profit growth (YoY) | +8.7% |
| Return on equity | 26.3% |
| ROCE | 33.0% |
| Debt / equity | 0.00 |
| Current ratio | 2.30 |
| Free cash flow | ₹77 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹5.7 cr |
Against Healthcare peers
| Metric | INDRAMEDCO | Peer median | Percentile |
|---|---|---|---|
| Net margin | 12.98 | 12.89 | 52 |
| PBT margin | 17.46 | 17.68 | 48 |
| ROE | 26.32 | 13.87 | 89 |
| ROCE | 32.95 | 17.26 | 88 |
| Debt / equity | 0.00 | 0.11 | 12 |
| FCF margin | 9.38 | -0.87 | 60 |
| Cash conversion | 1.00 | 1.25 | 32 |
| Trailing P/E | 14.58 | 43.26 | 3 |
Questions
What is the P/E ratio of Indraprastha Medical Corporation Limited?
Indraprastha Medical Corporation Limited's trailing P/E is 14.6, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 16 May 2025 its P/E has ranged 14.4–35.5.
What were Indraprastha Medical Corporation Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Indraprastha Medical Corporation Limited reported revenue of ₹413 cr and net profit of ₹54 cr (standalone), filed with the exchange on 29 Oct 2026.
What is Indraprastha Medical Corporation Limited's ROE?
Return on equity is 26.3% based on the balance sheet dated 30 Sept 2026.
Does Indraprastha Medical Corporation Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 30 Sept 2026.
What is INDRAMEDCO's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, INDRAMEDCO traded between ₹294.80 and ₹640.85.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: standalone SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.